下痢(Diarrhea)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Diarrhea Overview 8
Therapeutics Development 9
Pipeline Products for Diarrhea – Overview 9
Pipeline Products for Diarrhea – Comparative Analysis 10
Diarrhea – Therapeutics under Development by Companies 11
Diarrhea – Therapeutics under Investigation by Universities/Institutes 15
Diarrhea – Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Diarrhea – Products under Development by Companies 19
Diarrhea – Products under Investigation by Universities/Institutes 22
Diarrhea – Companies Involved in Therapeutics Development 23
A. Menarini Industrie Farmaceutiche Riunite Srl 23
Ache Laboratorios Farmaceuticos S/A 24
Actelion Ltd 25
Aegis Therapeutics, LLC 26
Assembly Biosciences, Inc. 27
Chiesi Farmaceutici SpA 28
Chongqing Zhifei Biological Products Co., Ltd. 29
Cosmo Pharmaceuticals S.p.A 30
Cubist Pharmaceuticals, Inc. 31
DesignMedix, Inc. 32
DiscoveryBiomed, Inc. 33
Furiex Pharmaceuticals, Inc. 34
GlycoVaxyn AG 35
GP Pharm, S.A. 36
Helsinn Healthcare S.A. 37
Intercept Pharmaceuticals, Inc. 38
Ipsen S.A. 39
Mucosis B.V. 40
Napo Pharmaceuticals, Inc. 41
Nippon Shinyaku Co., Ltd. 42
Novartis AG 43
Paratek Pharmaceuticals, Inc. 44
Pfizer Inc. 45
Prokarium Ltd. 46
Sanofi Pasteur SA 47
Scandinavian Biopharma Holding AB 48
Shire Plc 49
Sigmoid Pharma Limited 50
Summit Corporation plc 51
Syntiron LLC 52
Ventria Bioscience 53
Diarrhea – Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Target 55
Assessment by Mechanism of Action 58
Assessment by Route of Administration 60
Assessment by Molecule Type 62
Drug Profiles 64
ACE-527 – Drug Profile 64
ACE-920 – Drug Profile 66
ACH-04 – Drug Profile 67
AKT-10081 – Drug Profile 68
ASP-7147 – Drug Profile 69
cadazolid – Drug Profile 70
clostridium difficile vaccine – Drug Profile 71
crofelemer DR – Drug Profile 72
Diarrhea Vaccine – Drug Profile 74
diarrhea vaccine – Drug Profile 75
Drugs for CDAD – Drug Profile 76
elsiglutide – Drug Profile 77
eluxadoline – Drug Profile 78
Escherichia coli vaccine – Drug Profile 80
ETEC Adhesin-Based Vaccine – Drug Profile 81
Etvax – Drug Profile 82
fidaxomicin – Drug Profile 84
GVXNSD-133 – Drug Profile 87
helicobacter pylori vaccine [Hel-305] (multivalent) – Drug Profile 88
ibodutant – Drug Profile 89
infectious diarrhea [serotype H11] (H10407 and E24377A) vaccine – Drug Profile 90
INX-201 – Drug Profile 91
iOWH0-32 – Drug Profile 92
lanreotide acetate – Drug Profile 94
obeticholic acid – Drug Profile 96
octreotide – Drug Profile 99
octreotide acetate MAR – Drug Profile 100
Peptide for Enterocolitis and Infectious Diarrhea – Drug Profile 101
PF-06425090 – Drug Profile 102
prulifloxacin – Drug Profile 103
PZ-7475 – Drug Profile 105
RBX-2660 – Drug Profile 106
Recombinant Peptide to Activate Mucin 3 for Enterocolitis and Infectious Diarrhea – Drug Profile 107
Recombinant Proteins for Infectious Diarrhea – Drug Profile 109
rifamycin – Drug Profile 110
Small Molecule to Inhibit EnaC and Activate CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease – Drug Profile 112
Small Molecules for Bacterial Infections – Drug Profile 113
Small Molecules for Diarrhea – Drug Profile 114
Small Molecules for Diarrhea – Drug Profile 115
Small Molecules to Inhibit CFTR for Secretory Diarrhea – Drug Profile 116
SMT-19969 – Drug Profile 117
surotomycin – Drug Profile 118
Tetracycline Derivatives for CDAD – Drug Profile 119
Typhetec – Drug Profile 120
Vaccine for Campylobacter Caused Diarrhea – Drug Profile 121
Vaccine to Target Capsular Vi Polysaccharide Antigen for Traveler’s Diarrhea – Drug Profile 123
VEN-100 – Drug Profile 124
VP-20621 – Drug Profile 126
Yersinia pestis vaccine – Drug Profile 127
Diarrhea – Recent Pipeline Updates 128
Diarrhea – Dormant Projects 155
Diarrhea – Discontinued Products 157
Diarrhea – Product Development Milestones 158
Featured News & Press Releases 158
Appendix 166
Methodology 166
Coverage 166
Secondary Research 166
Primary Research 166
Expert Panel Validation 166
Contact Us 167
Disclaimer 167